Shares of 2seventy bio were up almost 10% at $13.40 this morning, after the US immuno-oncology cell therapy company announced it has agreed to sell around13,934,427 shares of its common stock to a select group of institutional and accredited investors in a private placement. 16 March 2022
Krystal Biotech, which is focussed on redosable gene therapies for rare diseases, saw its shares rise as much as 4.6% to $62.61 on Monday, as is said it has reached a binding term sheet with fellow US biotech firm PeriphaGen - and former lab partner - to resolve all claims it copied the latter’s gene therapy technology litigation filed by PeriphaGen on May 20, 2020. 16 March 2022
Metagenomi, a California, USA-based genetic medicines company with a versatile portfolio of next-generation gene editing tools, today announced the appointment of Christine Foster, as chief business officer and Alan Cohen, as chief medical officer and senior vice president of Monogenic Diseases. 15 March 2022
Israeli specialty drugmaker RedHill Biopharma has entered into an exclusive license agreement with Kukbo Co (Kospi: 001140), a South Korean corporation, for oral opaganib for the treatment of COVID-19, in South Korea. 15 March 2022
US antibacterial and antiviral drug R&D firm Venatorx Pharmaceuticals today announced positive results from its pivotal Phase III study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis. 10 March 2022
Privately-held US biotech Teon Therapeutics has announced the appointment of Serge Messerlian as chief executive and member of the board of directors. 9 March 2022
Privately-held Icelandic biosimilars developer Alvotech Holdings says it has executed a US settlement agreement with AbbVie that grants Alvotech non-exclusive rights to market AVT02 (100mg/mL), its high-concentration, citrate-free biosimilar candidate for Humira (adalimumab) in the USA 9 March 2022
Confirming that BioNTech is not just a one trick pony - having been behind the discovery of the most successful COIVD-19 vaccines, the German biotech today announced the expansion of its strategic collaboration with Regeneron to advance the company’s FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor, in advanced non-small cell lung cancer (NSCLC). 8 March 2022
Private UK-based cell and gene therapy company Ixaka, previously known as Rexgenero, has announced that Advanced Therapy Medicinal Product (ATMP) classification has been granted by the European Medicines Agency (EMA) for its Chemically Encapsulated Lentiviral vector for Targeted In Vivo CAR T-cell therapy (CELTIC-19) targeted nanoparticle (TNP) product. 8 March 2022
German CNS specialist Neuraxpharm Group today announced the expansion of its business in Southeast Europe through the acquisition of Greece-headquartered Brain Therapeutics, a CNS-focused marketing and distribution company with longstanding expertise in commercialization of CNS products in Greece, Cyprus and the Balkan countries. 8 March 2022
Following the filing of a Citizen Petition last Friday by French drug major Sanofi calling on the US Food and Drug Administration to review the labels for influenza vaccines from Seqirus, a subsidiary of Australia’s CSL Limited, Seqirus has issued its own view. 8 March 2022
Spanish drugmaker PharmaMar’s shares closed down 7.5% at 54.90 euros on Friday, despite announcing the receipt of payment of $25 million (22 million euros) from its US partner, Jazz Pharmaceuticals (Nasdaq: JAZZ), after reaching the first commercial milestone, set out in its license agreement in relation to 2021 sales. 7 March 2022
Following Discussion with the US Food and Drug Administration, Karyopharm Therapeutics plans to initiate a new placebo-controlled randomized study of selinexor in the advanced or recurrent endometrial cancer p53 wild-type population. 3 March 2022
Shares of Synairgen, the UK respiratory company developing SNG001, leapt more than 36% to 25.16 pence by late morning trading, after it announced an update on SNG001 in the ACTIV-2 Phase III trial for COVID-19 and on SNG001 activity against Delta and Omicron variants. 3 March 2022
Privately-held Swiss ophthalmology company Oculis and private Spanish translational neuroscience R&D company, Accure Therapeutics, have announced a licensing agreement. 2 March 2022
Rondo Therapeutics, a new immune-oncology-focused biotech based in San Francisco, USA, today emerged from stealth mode with its announcement of an oversubscribed $67 million Series A round of funding. 2 March 2022
UK and USA-based clinical-stage biopharmaceutical company F-star Therapeutics has appointed James Sandy as chief development officer (CDO), effective March 1. 2 March 2022
Legend Biotech, a clinical stage CAR-T immuno-oncology biotech spun out of Hong Kong-listed GenScript Biotech, says that the US Food and Drug Administration has approved its first product, Carvykti (ciltacabtagene autoleucel; cilta-cel). 1 March 2022
Shares of Ireland-headquartered rare diseased biotech Amryt Pharma fell as much as 31% yesterday, after it announced the receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration regarding its New Drug Application (NDA) for Oleogel-S10. 1 March 2022
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024